Next‐generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity

por Catenacci, Daniel V.T.
Publicado 2014

Immune-Checkpoint Inhibition in the Treatment of Gastro-Esophageal Cancer: A Closer Look at the Emerging Evidence

por Paydary, Koosha, Reizine, Natalie, Catenacci, Daniel V. T.
Publicado 2021

Initial Report of Second‐Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi‐Institutional Retrospective Analysis

por Klempner, Samuel J., Maron, Steven B., Chase, Leah, Lomnicki, Samantha, Wainberg, Zev A., Catenacci, Daniel V.T.
Publicado 2018

Acquisition of Portal Venous Circulating Tumor Cells From Patients With Pancreaticobiliary Cancers by Endoscopic Ultrasound

por Catenacci, Daniel V. T., Chapman, Christopher G., Xu, Peng, Koons, Ann, Konda, Vani J., Siddiqui, Uzma D., Waxman, Irving
Publicado 2015

MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma

por Catenacci, Daniel V. T., Ang, Agnes, Liao, Wei‐Li, Shen, Jing, O'Day, Emily, Loberg, Robert D., Cecchi, Fabiola, Hembrough, Todd, Ruzzo, Annamaria, Graziano, Francesco
Publicado 2016

Developing SHP2-based combination therapy for KRAS-amplified cancer

por Li, Tianxia, Kikuchi, Osamu, Zhou, Jin, Wang, Yichen, Pokharel, Babita, Bastl, Klavdija, Gokhale, Prafulla, Knott, Aine, Zhang, Yanxi, Doench, John G., Ho, Zandra V., Catenacci, Daniel V.T., Bass, Adam J.
Publicado 2023

Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma

por Catenacci, Daniel V.T., Rasco, Drew, Lee, Jeeyun, Rha, Sun Young, Lee, Keun-Wook, Bang, Yung Jue, Bendell, Johanna, Enzinger, Peter, Marina, Neyssa, Xiang, Hong, Deng, Wei, Powers, Janine, Wainberg, Zev A.
Publicado 2020

FGFR2‐Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape

por Klempner, Samuel J., Madison, Russell, Pujara, Vivek, Ross, Jeffrey S., Miller, Vincent A., Ali, Siraj M., Schrock, Alexa B., Kim, Seung Tae, Maron, Steven B., Dayyani, Farshid, Catenacci, Daniel V.T., Lee, Jeeyun, Chao, Joseph
Publicado 2019

Epacadostat Plus Pembrolizumab and Chemotherapy for Advanced Solid Tumors: Results from the Phase I/II ECHO-207/KEYNOTE-723 Study

por Powderly, John D, Klempner, Samuel J, Naing, Aung, Bendell, Johanna, Garrido-Laguna, Ignacio, Catenacci, Daniel V T, Taylor, Matthew H, Lee, James J, Zheng, Fred, Zhou, Feng, Gong, Xiaohua, Gowda, Hema, Beatty, Gregory L
Publicado 2022

Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma

por Catenacci, Daniel V., Chao, Joseph, Muro, Kei, Al‐Batran, Salah Eddin, Klempner, Samuel J., Wainberg, Zev A., Shah, Manish A., Rha, Sun Young, Ohtsu, Atsushi, Liepa, Astra M., Knoderer, Holly, Chatterjee, Anindya, Van Cutsem, Eric
Publicado 2021

Implementation of pharmacogenomic testing in oncology care (PhOCus): study protocol of a pragmatic, randomized clinical trial

por Reizine, Natalie, Vokes, Everett E., Liu, Ping, Truong, Tien M., Nanda, Rita, Fleming, Gini F., Catenacci, Daniel V.T., Pearson, Alexander T., Parsad, Sandeep, Danahey, Keith, van Wijk, Xander M. R., Yeo, Kiang-Teck J., Ratain, Mark J., O’Donnell, Peter H.
Publicado 2020

Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer

por Shah, Manish A., Wainberg, Zev A., Catenacci, Daniel V. T., Hochster, Howard S., Ford, James, Kunz, Pamela, Lee, Fa-Chyi, Kallender, Howard, Cecchi, Fabiola, Rabe, Daniel C., Keer, Harold, Martin, Anne-Marie, Liu, Yuan, Gagnon, Robert, Bonate, Peter, Liu, Li, Gilmer, Tona, Bottaro, Donald P.
Publicado 2021

Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer

por Shah, Manish A., Wainberg, Zev A., Catenacci, Daniel V. T., Hochster, Howard S., Ford, James, Kunz, Pamela, Lee, Fa-Chyi, Kallender, Howard, Cecchi, Fabiola, Rabe, Daniel C., Keer, Harold, Martin, Anne-Marie, Liu, Yuan, Gagnon, Robert, Bonate, Peter, Liu, Li, Gilmer, Tona, Bottaro, Donald P.
Publicado 2022

Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric Cancers

por Huffman, Brandon M., Aushev, Vasily N., Budde, Griffin L., Chao, Joseph, Dayyani, Farshid, Hanna, Diana, Botta, Gregory P., Catenacci, Daniel V.T., Maron, Steven B., Krinshpun, Shifra, Sharma, Shruti, George, Giby V., Malhotra, Meenakshi, Jurdi, Adham, Moshkevich, Solomon, Aleshin, Alexey, Kasi, Pashtoon M., Klempner, Samuel J.
Publicado 2022

Absolute Quantitation of Met Using Mass Spectrometry for Clinical Application: Assay Precision, Stability, and Correlation with MET Gene Amplification in FFPE Tumor Tissue

por Catenacci, Daniel V. T., Liao, Wei-Li, Thyparambil, Sheeno, Henderson, Les, Xu, Peng, Zhao, Lei, Rambo, Brittany, Hart, John, Xiao, Shu-Yuan, Bengali, Kathleen, Uzzell, Jamar, Darfler, Marlene, Krizman, David B., Cecchi, Fabiola, Bottaro, Donald P., Karrison, Theodore, Veenstra, Timothy D., Hembrough, Todd, Burrows, Jon
Publicado 2014

Phase II Prospective, Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy With and Without Sequential Cytoreductive Interventions for Patients with Oligo...

por Dhiman, Ankit, Vining, Charles C., Witmer, Hunter D. D., Sood, Divya, Shergill, Ardaman, Kindler, Hedy, Roggin, Kevin K., Posner, Mitchell C., Ahmed, Osmanuddin S., Liauw, Stanley, Pitroda, Sean, Liao, Chih-Yi, Karrison, Theodore, Weichselbaum, Ralph, Polite, Blase, Eng, Oliver S., Catenacci, Daniel V. T., Turaga, Kiran K.
Publicado 2022

Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase...

por Bang, Yung-Jue, Kang, Yoon-Koo, Catenacci, Daniel V., Muro, Kei, Fuchs, Charles S., Geva, Ravit, Hara, Hiroki, Golan, Talia, Garrido, Marcelo, Jalal, Shadia I., Borg, Christophe, Doi, Toshihiko, Yoon, Harry H., Savage, Mary J., Wang, Jiangdian, Dalal, Rita P., Shah, Sukrut, Wainberg, Zev A., Chung, Hyun Cheol
Publicado 2019

Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer

por Catenacci, Daniel V.T., Junttila, Melissa R., Karrison, Theodore, Bahary, Nathan, Horiba, Margit N., Nattam, Sreenivasa R., Marsh, Robert, Wallace, James, Kozloff, Mark, Rajdev, Lakshmi, Cohen, Deirdre, Wade, James, Sleckman, Bethany, Lenz, Heinz-Josef, Stiff, Patrick, Kumar, Pankaj, Xu, Peng, Henderson, Les, Takebe, Naoko, Salgia, Ravi, Wang, Xi, Stadler, Walter M., de Sauvage, Frederic J., Kindler, Hedy L.
Publicado 2015

Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial

por Zhu, Andrew X., Macarulla, Teresa, Javle, Milind M., Kelley, R. Kate, Lubner, Sam J., Adeva, Jorge, Cleary, James M., Catenacci, Daniel V. T., Borad, Mitesh J., Bridgewater, John A., Harris, William P., Murphy, Adrian G., Oh, Do-Youn, Whisenant, Jonathan R., Lowery, Maeve A., Goyal, Lipika, Shroff, Rachna T., El-Khoueiry, Anthony B., Chamberlain, Christina X., Aguado-Fraile, Elia, Choe, Sung, Wu, Bin, Liu, Hua, Gliser, Camelia, Pandya, Shuchi S., Valle, Juan W., Abou-Alfa, Ghassan K.
Publicado 2021